Skip to main content

Table 1 Comparison of survival outcomes between the AA + prednisone and prednisone-alone groups

From: Abiraterone acetate for chemotherapy-naive metastatic castration-resistant prostate cancer: a single-centre prospective study of efficacy, safety, and prognostic factors

 

Median OS, months(IQR)

Median PSA PFS,months(IQR)

Median rPFS, months(IQR)

PSA response rate

AA

  + prednisone group

23.3 (18.8~ 27.7)

10.3 (7.7~ 12.9)

13.9 (8.4~ 19.5)

62.79% (27 of 43)

 Prednisone-alone group

17.5 (13.2~ 21.8)

3.0 (1.7~ 4.4)

3.9 (3.0~ 4.4)

11.76% (2 of 17)

P value

0.016

< 0.001

< 0.001

< 0.001

  1. Abbreviations: AA abiraterone acetate, OS overall survival, PSA PFS PSA progression free survival, rPFS radiographic progression free survival, IQR interquartile range